•  
  •  
 

Article Type

Original Study

Abstract

Objective To assess the impact of Helicobacter pylori (Hp) eradication on the patient's quality of life. Background Functional dyspepsia (FD) is a common clinical problem that is seldom life-threatening, but impairs health-related quality of life. It was found that Hp gastritis was present in 30–60% of patients with FD. Patients and methods This study was carried out on 318 patients (18–55 years old) who fulfilled the ROME III diagnostic criteria for FD. They attended the Munshaat Sultan Family Health Center, Menouf district, Menoufia, Egypt, during the period from January 2013 to January 2014. Patients were invited to complete a baseline quality of life in patients with reflux and dyspepsia questionnaire (QOLRAD), and were classified as Hp+ and Hp− by Hp stool antigen testing. Hp+ patients received a 1-week course of Hp eradication. Hp+ and Hp− patients received a 4-week course of proton pump inhibitors (PPIs), prokinetics, and lifestyle modification, followed by on-demand therapy (PPIs, prokinetics) and lifestyle modification for 6 months. Reassessment of the patient's quality of life using the QOLRAD questionnaire by the two groups was performed 6 weeks and 6 months from the start of the treatment. Results Out of 318 patients with FD attended Munshaat Sultan Family Health Center a006Ed fulfilled ROME III criteria the percentage of Hp was 41.8%. QOLRAD were significantly lower in Hp+ than Hp− patients (P < 0.001). There was a highly statistically significant improvement in QOLRAD and dyspeptic symptoms 6 weeks and 6 months after the intervention among Hp+ and Hp− patients (P < 0.001) Conclusion In patients with FD, Hp eradication in infected patients and PPIs and prokinetics in Hp− patients reversed low QOL scores and improved global QOL during the 6-month follow-up period. Thus, we recommend the test and treat strategy for Hp for the management of patients with FD attending primary care clinics.

Download

Share

COinS